M&A

J.P. Morgan Reports Strong Biopharma and Medtech Investment in First Half of 2026

J.P. Morgan reports show biopharma and medtech investment remained strong in H1 2026, with licensing, M&A, venture funding, and IPOs all showing resilience, though investors favored later-stage assets.